In a report released today, David Martin PhD from Bloom Burton maintained a Buy rating on Zymeworks, with a price target of $30.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
David Martin PhD has given his Buy rating due to a combination of factors related to Zymeworks’ promising clinical trial results. The Phase 3 HERIZON-GEA-01 study demonstrated that Ziihera, when combined with chemotherapy or with both tislelizumab and chemotherapy, showed statistically significant and clinically meaningful improvements in progression-free survival compared to the current standard of care.
Additionally, the combination of Ziihera with tislelizumab and chemotherapy also resulted in a significant overall survival benefit, while Ziihera with chemotherapy alone showed a strong trend towards improved overall survival. These positive outcomes suggest a strong potential for Ziihera in treating HER2-positive locally advanced or metastatic gastroesophageal cancer, supporting the Buy rating for Zymeworks’ stock.
In another report released today, Citi also maintained a Buy rating on the stock with a $35.00 price target.